Pfizer Worldwide Medicinal Chemistry, Pfizer Worldwide R&D , Ramsgate Road, Sandwich CT13 9NJ, United Kingdom.
J Med Chem. 2012 Nov 26;55(22):9831-7. doi: 10.1021/jm3010515. Epub 2012 Nov 8.
The posttranslational modification of chromatin through acetylation at selected histone lysine residues is governed by histone acetyltransferases (HATs) and histone deacetylases (HDACs). The significance of this subset of the epigenetic code is interrogated and interpreted by an acetyllysine-specific protein-protein interaction with bromodomain reader modules. Selective inhibition of the bromo and extra C-terminal domain (BET) family of bromodomains with a small molecule is feasible, and this may represent an opportunity for disease intervention through the recently disclosed antiproliferative and anti-inflammatory properties of such inhibitors. Herein, we describe the discovery and structure-activity relationship (SAR) of a novel, small-molecule chemical probe for BET family inhibition that was identified through the application of structure-based fragment assessment and optimization techniques. This has yielded a potent, selective compound with cell-based activity (PFI-1) that may further add to the understanding of BET family function within the bromodomains.
组蛋白赖氨酸残基的乙酰化等翻译后修饰通过组蛋白乙酰转移酶(HATs)和组蛋白去乙酰化酶(HDACs)调控。该组蛋白翻译后修饰子集的重要性通过溴结构域读取模块与乙酰化赖氨酸特异性蛋白-蛋白相互作用来检测和解释。使用小分子选择性抑制溴和额外 C 端结构域(BET)家族的溴结构域是可行的,这可能代表通过最近发现的此类抑制剂的抗增殖和抗炎特性进行疾病干预的机会。在此,我们描述了一种新型小分子 BET 家族抑制剂化学探针的发现和构效关系(SAR),该探针是通过应用基于结构的片段评估和优化技术确定的。这产生了一种具有细胞活性的有效、选择性化合物(PFI-1),这可能进一步增加对溴结构域中 BET 家族功能的理解。